Get the Stockscreener App
12.43
3.86%
-0.47
After Hours:
12.59
0.16
+1.29%
Liquidia Corp stock is traded at $12.43, with a volume of 2.37M.
It is down -3.86% in the last 24 hours and down -16.32% over the past month.
See More
Previous Close:
$12.90
Open:
$12.5
24h Volume:
2.37M
Relative Volume:
2.67
Market Cap:
$1.10B
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-10.36
EPS:
-1.2
Net Cash Flow:
$-52.85M
1W Performance:
-15.92%
1M Performance:
-16.32%
6M Performance:
+11.23%
1Y Performance:
-21.06%
1-Day Range:
$11.95
$13.35
1-Week Range:
$11.95
$15.09
52-Week Range:
$8.26
$16.81
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
12.43 | 1.10B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
UPDATELiquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Liquidia says its request for Yutrepia final approval undergoes FDA review - MSN
Liquidia stock rises as Yutrepia undergoes FDA review (LQDA) - Seeking Alpha
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder - Investing.com
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA - TipRanks
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder By Investing.com - Investing.com Canada
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - Yahoo Finance
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
Liquidia Corporation (NASDAQ:LQDA) Q4 2024 Earnings Call Transcript - Insider Monkey
Liquidia (NASDAQ:LQDA) Price Target Raised to $34.00 - Defense World
Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result - GuruFocus.com
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects By Investing.com - Investing.com South Africa
What 4 Analyst Ratings Have To Say About Liquidia - Benzinga
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects - Investing.com
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Raymond James maintains strong buy on Liquidia stock, $27 target - Investing.com
H.C. Wainwright maintains Buy on Liquidia stock, $29 target - Investing.com
Raymond James maintains strong buy on Liquidia stock, $27 target By Investing.com - Investing.com UK
Liquidia Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Liquidia Corp (LQDA) - GuruFocus
Earnings call transcript: Liquidia Technologies Q4 2024 misses revenue forecast - Investing.com
Liquidia Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Liquidia Corp Reports Annual EPS of -$1.66 and Revenue of $14.0 Million, Missing Estimates - GuruFocus.com
Liquidia Corp SEC 10-K Report - TradingView
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update - TradingView
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million - The Manila Times
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? - Simply Wall St
Commit To Buy Liquidia At $7.50, Earn 11.3% Using Options - Nasdaq
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - The Manila Times
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - GlobeNewswire Inc.
Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) - GuruFocus.com
Liquidia’s chief commercial officer sells shares worth $9,146 By Investing.com - Investing.com Canada
Liquidia’s chief commercial officer sells shares worth $9,146 - Investing.com India
Liquidia Corp CFO Michael Kaseta sells shares worth $13,503 - Investing.com
Liquidia Corp Executives Sell Shares - TradingView
FDA Was Right to Delay Approving Liquidia's Yutrepia, Judge Says - Bloomberg Law
Liquidia Corp loses FDA lawsuit; Tyvaso DPI exclusivity stands - Investing.com
Liquidia Challenge To UTC's Tyvaso Exclusivity Fails - Law360
Bleakley Financial Group LLC Lowers Stock Position in Liquidia Co. (NASDAQ:LQDA) - Defense World
The Attractiveness of Investing In Liquidia Corp (LQDA) is Growing - Knox Daily
Analysts Set Liquidia Co. (NASDAQ:LQDA) Target Price at $25.38 - Armenian Reporter
Liquidia Co. (NASDAQ:LQDA) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Liquidia Corp's chief business officer sells $6,319 in stock - MSN
Life Sciences Group Of The Year: Cooley - Law360
Stock Performance Spotlight: Liquidia Corp (LQDA) Ends the Day at 15.74, Up by 3.89 - The Dwinnex
Liquidia Corp.: We Have Exposure To The Upside Now - Seeking Alpha
Liquidia Corp (LQDA) stock on the rise: An overview - US Post News
Arquitos Capital Management Q4 2024 Commentary - Seeking Alpha
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Liquidia Corp Stock (LQDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moomaw Scott | Chief Commercial Officer |
Mar 03 '25 |
Sale |
15.45 |
592 |
9,146 |
218,150 |
| Kaseta Michael | CFO and COO |
Mar 03 '25 |
Sale |
15.45 |
874 |
13,503 |
404,598 |
| Adair Jason | Chief Business Officer |
Mar 03 '25 |
Sale |
15.45 |
451 |
6,968 |
182,254 |
| Adair Jason | Chief Business Officer |
Jan 27 '25 |
Sale |
14.20 |
445 |
6,319 |
179,770 |
| Saggar Rajeev | Chief Medical Officer |
Jan 21 '25 |
Sale |
13.00 |
2,445 |
31,785 |
267,943 |
| Schundler Russell | General Counsel |
Jan 14 '25 |
Sale |
11.78 |
16,393 |
193,110 |
573,478 |
| Saggar Rajeev | Chief Medical Officer |
Jan 14 '25 |
Sale |
11.78 |
6,249 |
73,613 |
270,388 |
| Moomaw Scott | Chief Commercial Officer |
Jan 14 '25 |
Sale |
11.78 |
8,362 |
98,504 |
215,494 |
| Kaseta Michael | CFO and COO |
Jan 14 '25 |
Sale |
11.78 |
23,370 |
275,299 |
401,755 |
| Adair Jason | Chief Business Officer |
Jan 14 '25 |
Sale |
11.78 |
4,809 |
56,650 |
180,215 |
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):